DK3630112T3 - Kombination af regorafenib og nivolumab til behandling af cancer - Google Patents
Kombination af regorafenib og nivolumab til behandling af cancer Download PDFInfo
- Publication number
- DK3630112T3 DK3630112T3 DK18725258.0T DK18725258T DK3630112T3 DK 3630112 T3 DK3630112 T3 DK 3630112T3 DK 18725258 T DK18725258 T DK 18725258T DK 3630112 T3 DK3630112 T3 DK 3630112T3
- Authority
- DK
- Denmark
- Prior art keywords
- regorafenib
- nivolumab
- cancer
- treatment
- combination
- Prior art date
Links
- 239000002138 L01XE21 - Regorafenib Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229960003301 nivolumab Drugs 0.000 title 1
- 229960004836 regorafenib Drugs 0.000 title 1
- ZOPOQLDXFHBOIH-UHFFFAOYSA-N regorafenib hydrate Chemical compound O.C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 ZOPOQLDXFHBOIH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174169 | 2017-06-02 | ||
| PCT/EP2018/063785 WO2018219807A1 (en) | 2017-06-02 | 2018-05-25 | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3630112T3 true DK3630112T3 (da) | 2024-04-22 |
Family
ID=58992733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18725258.0T DK3630112T3 (da) | 2017-06-02 | 2018-05-25 | Kombination af regorafenib og nivolumab til behandling af cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US11951166B2 (da) |
| EP (2) | EP3630112B1 (da) |
| JP (2) | JP7303122B2 (da) |
| KR (1) | KR20200011971A (da) |
| CN (3) | CN117899212A (da) |
| AU (2) | AU2018276273B2 (da) |
| BR (1) | BR112019025478A8 (da) |
| CA (1) | CA3065125A1 (da) |
| DK (1) | DK3630112T3 (da) |
| FI (1) | FI3630112T3 (da) |
| IL (1) | IL270948A (da) |
| LT (1) | LT3630112T (da) |
| MX (1) | MX2023001721A (da) |
| PT (1) | PT3630112T (da) |
| WO (1) | WO2018219807A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3630112T (pt) | 2017-06-02 | 2024-04-23 | Bayer Healthcare Llc | Combinação de regorafenib e nivolumab para tratamento de cancro |
| CN111001004A (zh) * | 2019-10-08 | 2020-04-14 | 广州医科大学附属第二医院 | 一种治疗肝癌的药物组合及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| CA2628881A1 (en) | 2005-11-10 | 2007-05-18 | Bayer Healthcare Ag | Diaryl urea for treating diabetic neuropathy |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| UY35006A (es) * | 2012-09-06 | 2014-03-31 | Bayer Healthcare Llc | Composición farmacéutica recubierta que contiene regorafenib |
| PL2900269T3 (pl) * | 2012-09-25 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | Połączenie regorafenibu i kwasu acetylosalicylowego do leczenia raka jelita grubego |
| JP5653489B1 (ja) | 2013-07-24 | 2015-01-14 | 三菱エンジニアリングプラスチックス株式会社 | 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法 |
| CA3210360A1 (en) | 2014-02-04 | 2015-08-13 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| WO2015125652A1 (ja) * | 2014-02-21 | 2015-08-27 | Ｉｄａｃセラノスティクス株式会社 | 固形がんの治療剤 |
| SG11201700074YA (en) | 2014-07-15 | 2017-02-27 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| US10869926B2 (en) | 2014-07-15 | 2020-12-22 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| US20170231929A1 (en) * | 2014-08-19 | 2017-08-17 | National University Corporation Okayama University | Method for enhancing immune cell function and method for assessing immune cell multifunctionality |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| CA2966660A1 (en) | 2014-11-13 | 2016-05-19 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| WO2016173959A1 (en) * | 2015-04-28 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Regorafenib for treating colorectal cancer |
| WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| US20190183972A1 (en) | 2016-06-03 | 2019-06-20 | Imclone Llc | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers |
| US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| PT3630112T (pt) | 2017-06-02 | 2024-04-23 | Bayer Healthcare Llc | Combinação de regorafenib e nivolumab para tratamento de cancro |
| KR20200014414A (ko) * | 2017-06-05 | 2020-02-10 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 사용 방법 |
-
2018
- 2018-05-25 PT PT187252580T patent/PT3630112T/pt unknown
- 2018-05-25 LT LTEPPCT/EP2018/063785T patent/LT3630112T/lt unknown
- 2018-05-25 US US16/617,642 patent/US11951166B2/en active Active
- 2018-05-25 DK DK18725258.0T patent/DK3630112T3/da active
- 2018-05-25 CN CN202410088226.5A patent/CN117899212A/zh active Pending
- 2018-05-25 CA CA3065125A patent/CA3065125A1/en active Pending
- 2018-05-25 CN CN201880036504.5A patent/CN110662540B/zh active Active
- 2018-05-25 JP JP2019565949A patent/JP7303122B2/ja active Active
- 2018-05-25 EP EP18725258.0A patent/EP3630112B1/en active Active
- 2018-05-25 BR BR112019025478A patent/BR112019025478A8/pt unknown
- 2018-05-25 WO PCT/EP2018/063785 patent/WO2018219807A1/en active Application Filing
- 2018-05-25 KR KR1020197038281A patent/KR20200011971A/ko active IP Right Grant
- 2018-05-25 EP EP24150061.0A patent/EP4342542A2/en active Pending
- 2018-05-25 AU AU2018276273A patent/AU2018276273B2/en active Active
- 2018-05-25 FI FIEP18725258.0T patent/FI3630112T3/fi active
- 2018-05-25 CN CN202311446796.9A patent/CN117582495A/zh active Pending
-
2019
- 2019-11-26 IL IL270948A patent/IL270948A/en unknown
- 2019-12-02 MX MX2023001721A patent/MX2023001721A/es unknown
- 2019-12-31 US US16/731,409 patent/US20200155674A1/en not_active Abandoned
- 2019-12-31 US US16/731,412 patent/US11517622B2/en active Active
-
2022
- 2022-01-14 US US17/576,522 patent/US20220133888A1/en active Pending
- 2022-09-01 JP JP2022138972A patent/JP7475402B2/ja active Active
-
2023
- 2023-12-12 AU AU2023282197A patent/AU2023282197A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018219807A1 (en) | 2018-12-06 |
| US20200155674A1 (en) | 2020-05-21 |
| RU2019143599A (ru) | 2021-07-09 |
| JP7303122B2 (ja) | 2023-07-04 |
| PT3630112T (pt) | 2024-04-23 |
| AU2023282197A1 (en) | 2024-01-04 |
| EP4342542A2 (en) | 2024-03-27 |
| AU2018276273B2 (en) | 2023-12-21 |
| IL270948A (en) | 2020-01-30 |
| US20200179354A1 (en) | 2020-06-11 |
| CA3065125A1 (en) | 2018-12-06 |
| JP2020521786A (ja) | 2020-07-27 |
| FI3630112T3 (fi) | 2024-05-02 |
| CN110662540B (zh) | 2024-01-26 |
| BR112019025478A2 (pt) | 2020-06-23 |
| LT3630112T (lt) | 2024-05-10 |
| BR112019025478A8 (pt) | 2022-12-06 |
| KR20200011971A (ko) | 2020-02-04 |
| US11951166B2 (en) | 2024-04-09 |
| EP3630112B1 (en) | 2024-01-31 |
| EP3630112A1 (en) | 2020-04-08 |
| CN110662540A (zh) | 2020-01-07 |
| AU2018276273A1 (en) | 2019-12-12 |
| US11517622B2 (en) | 2022-12-06 |
| MX2023001721A (es) | 2023-02-22 |
| JP7475402B2 (ja) | 2024-04-26 |
| CN117582495A (zh) | 2024-02-23 |
| JP2022169780A (ja) | 2022-11-09 |
| US20220133888A1 (en) | 2022-05-05 |
| RU2019143599A3 (da) | 2021-09-10 |
| US20200188372A1 (en) | 2020-06-18 |
| CN117899212A (zh) | 2024-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3431105T3 (da) | Medicinsk sammensætning til behandling af cancer | |
| DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
| DK3402888T3 (da) | Middel og fremgangsmåder til behandling af hbv | |
| DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3285809T3 (da) | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| DK3518933T3 (da) | Fremgangsmåder til behandling af uterusfibromer og endometriose | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
| DK3277270T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3426777T3 (da) | Kombinationsvektorer og fremgangsmåder til behandling af cancer | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| DK3558280T3 (da) | Forebyggelse og behandling af migræne | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3380495T3 (da) | Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| DK3191103T3 (da) | Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner |